Aventis Files Fresh Patent Suit Against Mylan Over Generic Allegra

Law360 (September 6, 2005, 12:00 AM EDT) -- Aventis' patents for the lucrative allergy drug Allegra spawned new litigation last week against Mylan Pharmaceuticals, just as new plans were announced by rivals Barr and Teva to cooperate in manufacturing a generic version of some dosages.

France-based Aventis Pharmaceuticals Inc., which in 1996 launched the drug that generated about $1.4 billion in the past year, is once again taking action to protect six patents for certain dosages of Allegra and Allegra-D against West Virginia-based Mylan.

The complaint, filed in U.S. District Court for the District...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.